RADIORx’s compounds affect the vascular microenvironment through the selective release of oxidants such as the free radical nitric oxide or NO.

Read more...
 
 

RADIORx is a Silicon Valley-based discovery and development company that has developed a comprehensive portfolio of proprietary NASA-derived molecules with novel mechanisms of action.

Read more...
 
 

RADIORx is currently developing therapies for patients with different types of cancer. For further information about these treatments please visit our For Patients page.

Read more...
 
 

With the precision-guided accuracy of a smart bomb, RRx-001-erythrocytes target the hypoxic microenvironment in cancer and other diseases, potentiating a therapeutic response on site and sparing normal tissue

Read more...
 
 

RRx-001 has the potential to resensitize tumors to failed chemotherapy, turning back the clock and resetting the cancer timeline

Read more...
 
 

RADIORx has expanded its global footprint with strategies to treat orphan diseases such as sickle cell disease and malaria

Read more...